Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Ligand-targeted toxins (LTTs) are engineered molecules combining a targeting ligand with a cell-killing toxin.
• Bispecific targeting enables simultaneous engagement of two distinct cellular receptors.
• The epidermal growth factor receptor (EGFR) and urokinase-type plasminogen activator receptor (uPAR) are key targets in solid tumor progression.

Purpose of the Study:

• To review the development and efficacy of a bispecific LTT targeting both EGFR and uPAR.
• To evaluate the potential of this bispecific molecule, eBAT, in preclinical cancer models.
• To discuss future directions for optimizing eBAT therapy.

Main Methods:

• Development of a bispecific ligand-targeted toxin (eBAT) engineered to target EGFR and uPAR.
• In vitro and in vivo testing in mouse xenograft models of human solid tumors.
• Preclinical evaluation in canine hemangiosarcoma models due to physiological similarities with human angiosarcoma.

Main Results:

• EGFR-targeted bispecific angiotoxin (eBAT) demonstrated effectiveness against human solid tumors in vitro and in mouse xenografts.
• Canine studies confirmed eBAT's safety and efficacy in treating hemangiosarcoma.
• eBAT exhibits potential for targeting cancer stem cells and inhibiting tumor vasculature.

Conclusions:

• Bispecific LTTs, such as eBAT, represent a promising therapeutic strategy for solid tumors.
• The bispecific design may contribute to reduced toxicity, as suggested by comparative oncologic trials in dogs.
• Further research into dosing strategies and combination therapies is warranted to optimize eBAT's clinical application.